Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Tweet
Piers blombery, MBBS, PhD
Consultant Haematologist
Peter MacCallum Cancer Centre, Australia
NA
Poster(s):
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
